Des-γ-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma

Publisher： Karger

E-ISSN： 1421-9875|29|3|321-325

ISSN： 0257-2753

Source： Digestive Diseases, Vol.29, Iss.3, 2011-08, pp. : 321-325

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Decreased Blood Flow after Sorafenib Administration Is an Imaging Biomarker to Predict Overall Survival in Patients with Advanced Hepatocellular Carcinoma

By  

Digestive Diseases, Vol. 32, Iss. 6, 2014-10 ,pp. : 733-739

Karger

Access to resources Recommend Favorite

A Combination of α-Fetoprotein and Des-γ-Carboxy Prothrombin Is Superior in Detection of Hepatocellular Carcinoma

By  

Digestion, Vol. 87, Iss. 2, 2013-02 ,pp. : 121-131

Karger

Access to resources Recommend Favorite

Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma

By Ogasawara Sadahisa  

Hepatology International, Vol. 5, Iss. 3, 2011-09 ,pp. : 850-856

Springer Publishing Company

Access to resources Recommend Favorite

Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma

By Sinakos Emmanouil   Dedes Ioannis   Papalavrentios Lavrentis   Drevelegas Antonios   Akriviadis Evangelos  

Scandinavian Journal of Gastroenterology, Vol. 45, Iss. 4, 2010-04 ,pp. : 511-512

Informa Healthcare

Access to resources Recommend Favorite

Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice

By  

Digestive Diseases, Vol. 33, Iss. 5, 2015-09 ,pp. : 668-674

Karger

Access to resources Recommend Favorite